Loading stock data…
AMGN
$329.59-2.11 (-0.64%)
Market ClosedLast close May 11
Amgen Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Amgen Inc. in the Healthcare sector is trading at $329.59. The stock is currently 16% below its 52-week high of $391.29, remaining 2.0% above its 200-day moving average. Technical signals show neutral RSI of 37 and bearish MACD signal, explaining why AMGN maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 37) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$329.59
Potential Upside
37%
Whystock Fair Value$451.67
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus30 analysts
Buy
Mean target$353.07+7.1%
Range$200.00 – $432.00
Fundamentals
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$186.47B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.29
Beta
Defensive asset. Lower volatility than the S&P 500.
0.47
Div Yield
Strong income play. Yield provides a meaningful total return floor.
292.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
76.45%
Volume
Today's trading volume
1.92M
Recent News
3 Top Dividend Stocks to Maximize Your Retirement Income
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Will FDA-Backed Real-Time Trials in SCLC Reframe Amgen's (AMGN) R&D Narrative?
The U.S. FDA recently highlighted Amgen’s role in its real‑time clinical trials initiative, confirming the initiation of Amgen’s Phase 1b STREAM-SCLC study in limited-stage small cell lung cancer using real-time data signal sharing. This positions Amgen at the forefront of emerging “continuous” trial frameworks that aim to shorten development timelines and could change how oncology drugs are tested and reviewed. We’ll now examine how Amgen’s early involvement in real-time oncology trials...
Amgen’s Real Time FDA Trial Pilot Puts Oncology Execution In Focus
Amgen (NasdaqGS:AMGN) has been selected by the US Food and Drug Administration to participate in its real time clinical trials initiative. The company will apply the framework to its Phase 1b STREAM SCLC trial in small cell lung carcinoma. The initiative enables the FDA to receive trial data signals in real time, with the goal of improving trial efficiency and drug development timelines. Amgen focuses on biotechnology driven therapies, including oncology, where clinical trial design and...
2 Dividend Stocks to Double Up On Right Now
They can weather many storms.
Amgen’s US$300m Biologics Push And What It Means For AMGN Stock
Amgen announced a $300 million expansion of its U.S. biologics manufacturing network. The plan includes a significant new investment in a Puerto Rico facility to scale next generation technologies. The move is intended to support domestic medicine production and strengthen the American supply chain. For investors tracking NasdaqGS:AMGN, this manufacturing build out adds an operational angle to a stock that is currently trading at $329.59. Over the past year, the share price return of 25.7%...